Assistant Project
Resume:
GREGORY B. STAUBER, Ph.D.
*** ***** ******, ************ **. 22802
***********@*****.***
SUMMARY:
** + years of experience with emphasis on drug discovery
• Core skills include
o Tissue culture: mammalian, transformed, primary, embryonic, stem cell
o Protein purification, characterization, labeling
o Automation, hardware design
o Team management, project management
• Primary and secondary assay development, ligand binding, enzymatic, antibody,
cytotoxicity, neuronal outgrowth/degeneration, and synaptosomes/perfusion.
• PCR, screens involving multiple receptors, enzymes and pathways.
• Isolated reagent quantities of >30 receptors and enzymes; successfully utilized products
in drug screening programs.
• Identified, published, and/or patented lead compounds.
PROFESSIONAL EXPERIENCE:
Research Scientist 2008–2013
SRI International
Harrisonburg, Virginia
Implemented model system to confirm activity of PTH peptides.
•
Human mesenchymal stem cells (MSCs) were differentiated to osteoblasts and relative
changes in mRNA expression were quantified.
Designed and delivered database to associate human subject data (~1,000
•
variables/categories) with bio specimen collection of >20,000 samples. Stratified samples
and selected representatives for bioassays.
Mixed NOP/mu Compounds and the Involvement of Their Receptors in Analgesia.
•
Goal was to determine subtype specificity of compounds shown to have NOP and m-
opioid analgesic activity.
Subtype-Selective Nicotinic Receptor Ligands as Smoking Cessation Therapeutics.
•
Goal was to develop and characterize selective a3b4 nicotinic acetylcholine receptor
agonists/antagonists. Excluded activity of lead compound at this receptor in nucleus
accumbans.
Designed and constructed multichannel device to study nicotine mediated dopamine
•
release from synaptosome preparations.
Adapted the assay to examine agonists/antagonists as ion channel modulators.
Student 2007–2008
University of California, San Diego Extension
Bioinformatics
Principal Scientist 2005
Neose Inc.
San Diego, California
Initiated program to identify compounds to treat Parkinson's disease.
o Assays: binding, proliferation, ELISA, and neurotoxicity.
Private Consultant 2003–2005
• Provided expert advice on assay design, drug development, cell culture, and equipment
design.
• Performed literature searches and drafted feasibility reports, proposals, and
recommendations for initial program studies.
Senior Scientist 2000–2002
MitoKor, Inc.
San Diego, California
Drug-screening assays for neurodegeneration and metabolic diseases.
•
o Developed and conducted cell-based assays with neuronal cultures.
o Evaluated existing and potential targets/assay systems.
o Developed and validated automated cytotoxicity assay for primary embryonic
hippocampal neurons.
o Advised and trained others in areas related to drug discovery, protein purification,
and tissue culture.
Founder / Author 1999–2000
Carpathia
Danville, California
Initiated development interactive CD-ROMs presenting technical and scientific
•
information directed towards patients receiving neuropsychiatric medication.
Research Scientist II 1998–1999
Amgen
Thousand Oaks, California
Developed high-throughput, microfluidic platform to screen compound libraries.
•
Supervised three persons to develop and implement GPCR screening projects.
•
Developed and carried out methods to recover cell membranes containing high receptor
•
binding activities.
Significant accomplishments: receiving and validating working prototype microfluidic
•
screening platform; screening novel, proprietary GPCR, previously intractable to high-
throughput screening.
Senior Scientist 1997–1998
Soane BioSciences (now Monogram)
Hayward, California
Developed binding assays in a microfluidic, HTS platform.
•
Helped design novel biochemical methods, microfluidic patterns, instrumentation
•
platforms.
Coordinated efforts of highly diverse group of scientist and engineers.
•
Gregory B. Stauber, Ph.D. -2-
Principal Scientist 1988–1997
Chiron Corp.
Emeryville, California
Established and led a group to perform HTS of compound libraries generated within
•
Chiron and outside collaborators.
Led effort to bring automation to Chiron’s assay group.
•
Served as chairman of the G-Protein Coupled Receptor Screening Project.
•
Prioritized and evaluated new drug targets by focusing on receptor (binding) targets,
•
enzymatic systems, and whole cell functional assays.
Post Doctoral Research Scientist 1986–1988
Genentech, Inc.
South San Francisco, California
Purified receptor for tumor necrosis factor-alpha (TNF-alpha), using preparative
•
scale cell culture of a stable, high receptor expressing cell line, followed by ligand-
directed immunoaffinity chromatography of the crosslinked TNF-receptor complex.
Characterized receptor using isoelectric focusing, two-dimensional gel
•
electrophoresis, and FPLC.
Acquired practical experience in radiolabeling, ligand binding, crosslinking,
•
solubilization, and preparative SDS-PAGE.
Research Assistant 1980–1986
University of California, Riverside
Riverside, California
Purified GABA/benzodiazepine receptor from mammalian brain focusing primarily on
•
benzodiazepine affinity chromatography. Screened matrices and coupling
procedures, optimized protein adsorption and recovery.
Expertise in gel filtration, ion exchange, and lectin affinity chromatography, density
•
gradient centrifugation, HPLC, and in vitro MAb production.
Confirmed identity of semi-purified receptor by photoaffinity labeling solubilized
•
protein with tritiated benzodiazepine derivative.
Research Assistant 1977–1980
California State University, Hayward
Hayward, California
Purified and characterized human myeloperoxidase isolated from WBCs.
•
Developed final purification scheme and kinetic analysis of the protein
•
EDUCATION:
Ph.D. Biochemistry, University of California, Riverside
(Minor, Biomedical Sciences). Research Director - Professor Richard W.Olsen. Thesis Title:
"Purification of the Solubilized GABA/Benzodiazepine Receptor."
B.A. Neurobiology, University of California, Berkeley.
Gregory B. Stauber, Ph.D. -3-
Chemistry, biology, physics and math.
M.S. Biochemistry, California State University, Hayward.
Research Director - Dr. Larry Scheve. Thesis title: "A Kinetic Characterization of Leukocyte
Myeloperoxidase."
HONORS:
Chancellor's Patent Fund Award
Research Assistantship, University of California, Riverside
Foreign Language Honor Society, University of California, Berkeley
Contra Costa Medical Association Scholarship
PATENTS:
“Capillary assays involving separation of free and bound species,” E. Ullman, G. Stauber. US
Patent 6,103,537, Issued Aug 15, 2000.
“Opiate receptor ligands,” D.C. Spellmeyer, W.H. Moos, E.J. Martin, R.N. Zuckermann, G. Stauber,
K.R. Shoemaker, D. Goff. US Patent 5,536,853, Issued July 16, 1996.
“Peptoid alpha-1 adrenergic receptor ligands,” D.C. Spellmeyer, W. H. Moos, E.J. Martin, R. N.
Zuckermann, G. Stauber. US Patent 5,447,916, 5,480,871, Issued Sept 5, 1995.
PUBLICATIONS:
1.) Vazquez-Derose J, Stauber G, Khroyan TV, Xie XS, Zaveri NT, Toll L. Retrodialysis of
N/OFQ into the nucleus accumbens shell blocks cocaine-induced increases in extracellular
dopamine and locomotor activity. Eur J Pharmacol. 2013; 699:200-6
2.) Toll L, Zaveri NT, Polgar WE, Jiang F, Khroyan TV, Zhou W, Xie XS, Stauber GB, Costello
MR, Leslie FM. AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor
antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology, 2012;
37:1367-76.
3.) Mullenbach GT, Chiu CY, Gynes A, Blaney J, Rosenberg S, Marlowe CK, Brown S, Stratton
Thomas J, Montelione GT, George-Nascimento C, Stauber G. Modification of a receptor binding
surface of epidermal growth factor (EGF): analogs with enhanced receptor affinity at low pH or at
neutrality. Prot. Eng. 1998; 11:6 473-80.
4.) Zuckermann RN; Martin EJ; Spellmeyer DC; Stauber GB; Shoemaker KR; Kerr JM; Figliozzi
GM; Goff DA; Siani MA; Simon RJ; et al. Discovery of nanomolar ligands for 7-transmembrane G-
protein-coupled receptors from a diverse N-(substituted) glycine peptoid library. J Med. Chem.
1994; 37 (17) 2678-85.
Gregory B. Stauber, Ph.D. -4-
5.) Ishihara M; Tyrrell DJ; Stauber GB; Brown S; Cousens LS; Stack RJ. Preparation of affinity-
fractionated, heparin-derived oligosaccharides and their effects on selected biological activities
mediated by basic fibroblast growth factor. J. Biol. Chem. 1993; 268 (7) 4675-83.
6.) Tyrrell DJ; Ishihara M; Rao N; Horne A; Kiefer MC; Stauber GB; Lam LH; Stack RJ. Structure
and biological activities of a heparin-derived hexasaccharide with high affinity for basic fibroblast
growth factor. J. Biol. Chem. 1993; 268 (7) 4684-9.
7.) Kaufman SE; Brown S; Stauber GB. Characterization of ligand binding to extracellular domains
of three growth factor receptors. Anal. Biochem. 1993; 211 (2) 261-6.
8.)Stauber GB; Aggarwal BB (1989) Characterization and affinity cross-linking of receptors for
human recombinant lymphotoxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell
line, U-937. J. Biol. Chem. 1989; 264 (6) 3573-6.
9.) Stauber, GB; Aiyer, RA; Aggarwal, BB. Human tumor necrosis factor-alpha receptor:
Immunoaffinity purification and characterization. J. Biol. Chem. 1988; 263 (35) 19098-104.
10.) King RG; Nielsen M; Stauber GB; Olsen RW Convulsant/barbiturate activity on the soluble
gamma-aminobutyric acid- benzodiazepine receptor complex. Eur J Biochem. 1987; 169 (3) p555-
62
11.) Stauber, GB, Ransom, RW, Dilber, AI, and Olsen, RW The gamma-aminobutyric-acid
benzodiazepine-receptor protein from rat brain - large scale purification and preparation of
antibodies. Eur. J. Biochem. 1987; 167:125-133.
12.) Olsen, RW, Stauber, GB, Ransom, RW, Dilber, AI, Deng, L, Bureau, M, Smith, G,
Khrestchatisky, M, and Tobin, AJ. Biochemical properties of the GABA receptor-chloride channel
complex. In Pharmacology. M. J. Rand and C. Raper, editors. Elsevier, Amsterdam, 1987; 133-
136.
13.) King, R. G., Nielsen, M., Stauber, G. B., and Olsen, R. W. Convulsant/barbiturate activity on
the soluble gamma-aminobutyric acid-benzodiazepine receptor complex. Eur. J. Biochem. 1987;
169:555-562.
14.) Olsen, RW, Stauber, GB, King, RG, Yang, G, and Dilber, A Structure and function of the
barbiturate-modulated benzodiazepine/GABA receptor protein complex. Adv. Biochem.
Psychopharmacol. 1986; 41:21-32.
15.) Olsen, RW, Yang, J, King, RG, Dilber, A, Stauber, GB, and Ransom, RW Barbiturate and
benzodiazepine modulation of GABA receptor binding and function. Life Sci.1986; 39:1969-1976.
16.) Olsen, RW, Wong, EHF, Stauber, GB, Murakami, D, King, RG, and Fischer, JB Biochemical
properties of the GABA/barbiturate/benzodiazepine receptor-chloride ion channel complex. Adv.
Exp. Med. Biol. 1984; 175:205-219.
17.) Olsen, RW, Fischer, JB, King, RG, Ransom, JY, and Stauber, GB. Purification of the
GABA/benzodiazepine/barbiturate receptor complex. Neuropharmacology 1984; 23:853-854.
Gregory B. Stauber, Ph.D. -5-
18.) Olsen, RW, Wong, EHF, Stauber, GB, and King, RG (1984) Biochemical pharmacology of the
GABA/benzodiazepine receptor/ionophore protein. (FASEB Symposium) Fed. Proc. 1984;
43:2773-2778.
19.) Olsen, RW, Stauber, GB, Fischer, JB, King, RG, and Ransom, JY Purification and properties
of the GABA/benzodiazepine/barbiturate receptor protein from rat brain. Proceedings, Ninth
International Congress of Pharmacology (W. Paton, P. Turnes, eds.) Macmillan Press, London,
1984; pp. 171-177.
ABSTRACTS:
1.) Stauber, GB, Aiyer, RA, and Aggarwal, BB. Human tumor necrosis factor-alpha receptor:
Immunoaffinity purification and physicochemical characterization. 14th International Congress of
Biochemistry. 1988.
2.) McCabe, S, Rice, G, Stauber, GB, Schreiber, R, and Palladino, M Use of flow cytometry to
detect and enrich for cells expressing cytokine receptors: Tumor necrosis factor, gamma interferon,
and transforming growth factor beta. XIII International Meeting Soc. Anal. Cytology. 1988.
3.) King, RG, Stauber, GB, and Olsen, RW. Reversible conformational changes account for
convulsant/barbiturate receptor activities on the GABA/benzodiazepine receptor/ ionophore
complex. Abstr. Soc. Neurosci. 1985; 11:274, No. 79.12.
4.) Olsen, RW, Stauber, GB, Fischer, JB, King, RG, and Ransom, JY. Recent advances in
purification and biochemical properties of GABA receptors. Abstr. Ninth International Union of
Pharmacology, London, 1984; pp. S25-4.
5.) King, RG, Stauber, GB, Fischer, JB, and Olsen, RW Convulsant/barbiturate receptors are part
of the GABA-benzodiazepine receptor protein complex. Soc. Neurosci. Abstr. 1984; 10:971, No.
285.9.
6.) Fischer, JB, Stauber, GB, King, RG, and Olsen, RW. Purification of the
GABA/benzodiazepine/barbiturate receptor complex from rat brain. Soc. Neurosci. Abstr. 1984;
10:971, No. 285.10, Presented Poster.
7.) Olsen, RW, Fischer, JB, Ransom, JY, Stauber, GB, and King, RG Barbiturate enhancement of
GABA receptor binding and function. International Conference on Anaesthesia.1984
8.) Olsen, RW, Wong, EHF, Stauber, G, Murakami, D, and Sussman, J (1983) Progress in the
purification of the benzodiazepine/GABA receptor protein. Trans. Am. Soc. Neurochem. 1983;
14:194.
Gregory B. Stauber, Ph.D. -6-
Contact this candidate